Keyphrases
AIDS/HIV
82%
US Cities
56%
Ending the HIV Epidemic
54%
Naloxone
50%
Cost-effectiveness
45%
United States
41%
China
40%
Opioid Overdose
39%
Community-based
36%
Atlanta
33%
HIV Incidence
31%
Massachusetts
31%
Quality-adjusted Life Years
30%
Naloxone Distribution
29%
Antiretroviral Therapy
29%
Miami
28%
Pre-exposure Prophylaxis (PrEP)
27%
British Columbia
27%
HIV Prevention
27%
Rhode Island
25%
New York City
24%
HIV Transmission
24%
Cost-effectiveness Analysis
22%
Dynamic HIV Transmission Model
21%
Seattle
21%
Baltimore
20%
People Who Inject Drugs
20%
Human Immunodeficiency Virus Testing
18%
Viral Outbreaks
18%
Naloxone Access
18%
Credible Interval
18%
Health Economic Evaluation
16%
HIV Infection
16%
Treatment Engagement
16%
Canada
16%
Epidemiological Impact
15%
HIV Care
15%
Health Equity
15%
Public Health
14%
Evidence-based Interventions
13%
Incremental Cost-effectiveness Ratio
13%
AIDS Epidemic
13%
Optimal Combination
12%
Overdose Deaths
12%
Health Benefits
12%
HIV Epidemic
12%
HIV Transmission Networks
12%
Virus Incidence
12%
Racial Disparities
12%
Ending the Epidemic
12%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Cost-Effectiveness Analysis
50%
Naloxone
43%
Health Care Cost
37%
HIV Test
28%
Antiretroviral Therapy
24%
HIV/AIDS
17%
Quality Adjusted Life Year
17%
Human Immunodeficiency Virus Infection
14%
Ethnic Groups
9%
Mortality Rate
8%
Ethnic Disparity
8%
Infection
7%
Virus Transmission
7%
Fatality
7%
Human Immunodeficiency Virus Risk Behavior
7%
Opiate Agonist
7%
Pre-Exposure Prophylaxis
7%
High Risk Population
6%
Disease Exacerbation
6%
COVID-19
6%
Gene Linkage
6%
Drug Therapy
6%
Systematic Review
6%
Network Meta-Analysis
6%
Harm Reduction
6%
Wart Virus Vaccine
6%
Rebound
6%
Treatment Interruption
6%
Health Outcomes
6%
Mass Immunization
6%
White Population
6%
Drug Resistant Tuberculosis
6%
Wart Virus
5%